ERBB2 and breast carcinoma: Given that TP53 had different predictive value in patients with different HER2 statuses in this study, we believe that the utility of TP53 for predicting efficacy is heterogeneous and population‐specific and therefore cannot be generalized to all populations of patients with breast cancer.